Reverse hydroxamate derivatives as metalloprotease inhibitors

By  

Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 11, 1999-11 ,pp. : 1575-1578

Informa Healthcare

Access to resources Recommend Favorite

Clinical Potential of Matrix Metalloprotease Inhibitors in Cancer Therapy

By Heath E.I.  

Drugs, Vol. 59, Iss. 5, 2000-05 ,pp. : 1043-1055

Adis International

Access to resources Recommend Favorite

Therapeutic potential of matrix metalloprotease inhibitors in neuropathic pain

By Dev Rishabh   Srivastava Punit Kumar   Iyer Jitesh P   Dastidar Sunanda G   Ray Abhijit  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 4, 2010-04 ,pp. : 455-468

Informa Healthcare

Access to resources Recommend Favorite

Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer

By Kenny Paraic A  

Expert Opinion on Therapeutic Targets, Vol. 11, Iss. 10, 2007-10 ,pp. : 1287-1298

Informa Healthcare

Access to resources Recommend Favorite

Enhanced hit-to-lead process using bioanalogous lead evolution and chemogenomics: application in designing selective matrix metalloprotease inhibitors

By Papp Ákos   Szommer Tamás   Barna László   Gyimesi Gergely   Ferdinandy Péter   Spadoni Cesare   Darvas Ferenc   Fujita Toshio   Ürge László   Dormán György  

Expert Opinion on Drug Discovery, Vol. 2, Iss. 5, 2007-05 ,pp. : 707-723

Informa Healthcare

Access to resources Recommend Favorite